JPSIM Journal of Pakistan Society of Internal Medicine J Pak Soc Intern Med 2709-8729 2710-0804 Pakistan Society of Internal Medicine 10.70302/jpsim.v6i3.2548 jpsim.v6i3.2548 Original Research Paricalcitol Versus Calcitrol in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Dependent Patients Javaid Bilal dr.bilaljavaid160@gmail.com * Irfan Muhammad Elahi Irfan Akrum Sara Hassan Sumaira Nabi Ijaz Faisal Abad Medical University, Faisal Abad King Edward Medical University, Lahore *Correspondence: Bilal Javaid (dr.bilaljavaid160@gmail.com) 23 08 2025 2025 6 3 259 262 18 09 2024 05 02 2025 21 07 2025 Copyright © 2025 The Author(s) 2025 The Author(s) https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective

To compare the efficacy of paricalcitol with calcitriol for treatment of secondary hyperparathyroidism in dialysis patients.

 Methodology

This Randomized Controlled Trial (RCT) was carried out in Department of Nephrology, FMU & Allied Hospital, Faisalabad in six months period from 13th November 2023 to 12th May 2024. A total of 100 dialysis dependent patients having secondary hyperparathyroidism were included and divided into two groups. Patients in Group A received paricalcitol at a dose of 1µg/day for a period of 12 weeks. Patients in Group B took calcitriol at a dosage of 0.5 micrograms per day for a period of 12 weeks. The effectiveness was evaluated after a treatment period of twelve weeks.

 Results

The mean age of patients in group A was 48.48 ± 6.57 years and in group B was 48.0 ± 8.01 years. Out of these 100 patients, 52 (52.0%) were males and 48 (48.0%) were females. Efficacy in Paricalcitol was seen in 41 (82.0%) patients and in Calcitriol was seen in 29 (58.0%) patients with p-value of 0088 which is statistically significant.

 Conclusion

This study concluded that paricalcitol is better than calcitriol for treatment of secondary hyperparathyroidism in dialysis patients.

 Keywords Dialysis Secondary Hyperparathyroidism Paricalcitol. Ethics Statement

Ethics committee: Research Ethics Committee, Faisalabad Medical University, Faisalabad, Pakistan. Approval number: 48/REC/FMU/2023-24/309, dated September 5, 2023.

 References Yang C-W, Harris DC, Luyckx VA, Nangaku M, Hou FF, Garcia GG, et al. Global case studies for chronic kidney disease/end-stage kidney disease care. Kidney Int Suppl. 2020;10(1):e24-e48. Fernandez-Fernandez B, Sarafidis P, Kanbay M, Navarro-González JF, Soler MJ, Górriz JL, et al. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. Oxford University Press; 2020. p. 728-33. Bozic M, Diaz-Tocados JM, Bermudez-Lopez M, Forné C, Martinez C, Fernandez E, et al. Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort. Nephrol Dialy Transplant. 2022;37(4):663-72. Zhang Z, Cai L, Wu H, Xu X, Fang W, He X, et al. Paricalcitol versus calcitriol+ cinacalcet for the treatment of secondary hyperparathyroidism in chronic kidney disease in China: a cost-effectiveness analysis. Front Public Health. 2021;9:712027. Kashif MA. To compare anti-albumin urea effects of valsartan alone with combination of valsartan and amlodipine in patients of chronic kidney disease. Pak J Med Sci. 2016;32(3):613. Imtiaz S, Alam A. Epidemiology and demography of Chronic Kidney Disease in Pakistan-A review of Pakistani literature. Pak J Kidney Dis. 2023;7(1):2-7. Zhang T, Ju H, Chen H, Wen W. Comparison of paricalcitol and calcitriol in dialysis patients with secondary hyperparathyroidism: a meta‐analysis of randomized controlled studies. Therap Apher Dialy. 2019;23(1):73-9. Qaisar MA, ul Abideen Z, Chattah FS, Nadeem M, Qaisar ZHMA, ul Abideen Z, et al. Comparison of Paricalcitol (IV) and Alfacalcidol (IV) in Treatment of Secondary Hyperparathyroidism (SHPT) in Hemodialysis Patients. J Rawalpindi Med Coll. 2020;24(4):378-83. Liu Y, Liu L-Y, Jia Y, Wu M-Y, Sun Y-Y, Ma F-Z. Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis. Drug Desi Develop Ther. 2019;13:999-1009. Martín-Carro B, Navarro-González JF, Ortiz A, Zoccali C, Floege J, Ferreira MA, et al. Mineral and bone metabolism markers and mortality in diabetic patients on haemodialysis. Nephrol Dialy Transplant. 2023;38(11):2589-97. Vazquez MA, Oliver G, Amarasingham R, Sundaram V, Chan K, Ahn C, et al. Pragmatic Trial of Hospitalization Rate in Chronic Kidney Disease. N Engl J Med. 2024;390(13):1196-206. Eidman KE, Wetmore JB. Managing hyperparathyroidism in hemodialysis: role of etelcalcetide. Int J Nephrol Renovasc Dis. 2018:69-80. Pérez-Ricart A, Galicia-Basart M, Alcalde-Rodrigo M, Segarra-Medrano A, Sune-Negre J-M, Montoro-Ronsano J-B. Effectiveness of cinacalcet in patients with chronic kidney disease and secondary hyperparathyroidism not receiving dialysis. PLoS One. 2016;11(9):e0161527. Kubodera N. A new look at the most successful prodrugs for active vitamin D (D hormone): alfacalcidol and doxercalciferol. Molecules. 2009;14(10):3869-80. Dusilová‐Sulková S. Vitamin D metabolism and vitamin D traditional and nontraditional, target organs: implications for kidney patients. J Renal Care. 2009;35:39-44. Cardoso MMdA, Machado-Rugolo J, Lima SAM, Andrade LGMd, Curado DdSP, Ponce D. Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease. Braz J Nephrol. 2022;45:95-101. Hassan AB, Ghalib KW, Jahrami HA, El-Agroudy AE. Prevalence of Musculoskeletal Manifestations in adult kidney transplant’s recipients: a systematic review. Medicina. 2021;57(6):525. Franchi M, Gunnarsson J, Gonzales-Parra E, Ferreira A, Ström O, Corrao G. Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis. J Clin Endocrinol Metabol. 2023;108(11):e1424-e32. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349(5):446-56. Tentori F, Hunt W, Stidley C, Rohrscheib M, Bedrick E, Meyer K, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006;70(10):1858-65.